In patients with Philadelphia chromosome-positive (Ph+) CD20+ B-ALL, rituximab is combined with chemotherapy and BCR-ABL1 tyrosine kinase inhibitors, such as imatinib and dasatinib. Here, MS4A1 is linked to acute lymphoblastic leukemia.